(TXN) Texas Instruments - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8825081040
Stock: Analog Chips, Embedded Processors, Calculators, Imaging Chips
Total Rating 53
Risk 78
Buy Signal -0.69
| Risk 5d forecast | |
|---|---|
| Volatility | 34.2% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.27 |
| Alpha | -13.29 |
| Character TTM | |
|---|---|
| Beta | 1.133 |
| Beta Downside | 1.743 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.41% |
| CAGR/Max DD | 0.24 |
EPS (Earnings per Share)
Revenue
Description: TXN Texas Instruments March 05, 2026
Texas Instruments (TXN) designs, manufactures, and sells semiconductors globally, serving electronics designers and manufacturers. The company operates in two segments: Analog and Embedded Processing. The semiconductor industry is cyclical, driven by demand for electronic devices.
The Analog segment provides power management and signal chain products. These include battery management solutions, voltage regulators, amplifiers, and data converters. Analog semiconductors are essential for converting real-world signals into digital data.
The Embedded Processing segment offers microcontrollers, processors, wireless connectivity, and radar products. This segment also includes DLP products for imaging and application-specific integrated circuits. The companys business model involves direct sales, distributors, and online channels.
TXN products are utilized across diverse markets, including industrial, automotive, personal electronics, and communications equipment. The automotive sector, for example, increasingly relies on semiconductors for advanced driver-assistance systems and electric vehicles. For further in-depth analysis of TXNs performance and market position, consider exploring ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 5.00b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.31 > 1.0 |
| NWC/Revenue: 59.90% < 20% (prev 72.78%; Δ -12.88% < -1%) |
| CFO/TA 0.21 > 3% & CFO 7.15b > Net Income 5.00b |
| Net Debt (12.17b) to EBITDA (8.25b): 1.47 < 3 |
| Current Ratio: 4.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (913.0m) vs 12m ago -0.65% < -2% |
| Gross Margin: 57.02% > 18% (prev 0.58%; Δ 5644 % > 0.5%) |
| Asset Turnover: 50.45% > 50% (prev 44.05%; Δ 6.40% > 0%) |
| Interest Coverage Ratio: 11.52 > 6 (EBITDA TTM 8.25b / Interest Expense TTM 543.0m) |
Altman Z'' 10.00
| A: 0.31 (Total Current Assets 13.75b - Total Current Liabilities 3.16b) / Total Assets 34.59b |
| B: 1.51 (Retained Earnings 52.24b / Total Assets 34.59b) |
| C: 0.18 (EBIT TTM 6.25b / Avg Total Assets 35.05b) |
| D: 2.94 (Book Value of Equity 53.89b / Total Liabilities 18.31b) |
| Altman-Z'' Score: 11.22 = AAA |
Beneish M -3.00
| DSRI: 1.01 (Receivables 1.96b/1.72b, Revenue 17.68b/15.64b) |
| GMI: 1.02 (GM 57.02% / 58.14%) |
| AQI: 0.96 (AQ_t 0.25 / AQ_t-1 0.26) |
| SGI: 1.13 (Revenue 17.68b / 15.64b) |
| TATA: -0.06 (NI 5.00b - CFO 7.15b) / TA 34.59b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = A |
What is the price of TXN shares?
As of March 05, 2026, the stock is trading at USD 202.39 with a total of 5,420,872 shares traded.
Over the past week, the price has changed by -5.38%, over one month by -9.21%, over three months by +13.10% and over the past year by +7.16%.
Over the past week, the price has changed by -5.38%, over one month by -9.21%, over three months by +13.10% and over the past year by +7.16%.
Is TXN a buy, sell or hold?
Texas Instruments has received a consensus analysts rating of 3.43.
Therefor, it is recommend to hold TXN.
- StrongBuy: 10
- Buy: 2
- Hold: 21
- Sell: 2
- StrongSell: 2
What are the forecasts/targets for the TXN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 221.6 | 9.5% |
| Analysts Target Price | 221.6 | 9.5% |
TXN Fundamental Data Overview February 28, 2026
P/E Trailing = 38.9908
P/E Forward = 33.67
P/S = 10.8997
P/B = 11.8584
P/EG = 1.7117
Revenue TTM = 17.68b USD
EBIT TTM = 6.25b USD
EBITDA TTM = 8.25b USD
Long Term Debt = 13.55b USD (from longTermDebt, last quarter)
Short Term Debt = 619.0m USD (from shortTermDebt, last quarter)
Debt = 15.39b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.17b USD (from netDebt column, last quarter)
Enterprise Value = 203.24b USD (192.73b + Debt 15.39b - CCE 4.88b)
Interest Coverage Ratio = 11.52 (Ebit TTM 6.25b / Interest Expense TTM 543.0m)
EV/FCF = 78.08x (Enterprise Value 203.24b / FCF TTM 2.60b)
FCF Yield = 1.28% (FCF TTM 2.60b / Enterprise Value 203.24b)
FCF Margin = 14.72% (FCF TTM 2.60b / Revenue TTM 17.68b)
Net Margin = 28.28% (Net Income TTM 5.00b / Revenue TTM 17.68b)
Gross Margin = 57.02% ((Revenue TTM 17.68b - Cost of Revenue TTM 7.60b) / Revenue TTM)
Gross Margin QoQ = 55.89% (prev 57.42%)
Tobins Q-Ratio = 5.88 (Enterprise Value 203.24b / Total Assets 34.59b)
Interest Expense / Debt = 0.92% (Interest Expense 141.0m / Debt 15.39b)
Taxrate = 15.23% (209.0m / 1.37b)
NOPAT = 5.30b (EBIT 6.25b * (1 - 15.23%))
Current Ratio = 4.35 (Total Current Assets 13.75b / Total Current Liabilities 3.16b)
Debt / Equity = 0.95 (Debt 15.39b / totalStockholderEquity, last quarter 16.27b)
Debt / EBITDA = 1.47 (Net Debt 12.17b / EBITDA 8.25b)
Debt / FCF = 4.67 (Net Debt 12.17b / FCF TTM 2.60b)
Total Stockholder Equity = 16.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.27% (Net Income 5.00b / Total Assets 34.59b)
RoE = 30.44% (Net Income TTM 5.00b / Total Stockholder Equity 16.43b)
RoCE = 20.86% (EBIT 6.25b / Capital Employed (Equity 16.43b + L.T.Debt 13.55b))
RoIC = 17.57% (NOPAT 5.30b / Invested Capital 30.17b)
WACC = 9.40% (E(192.73b)/V(208.12b) * Re(10.09%) + D(15.39b)/V(208.12b) * Rd(0.92%) * (1-Tc(0.15)))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.11%
[DCF] Terminal Value 69.40% ; FCFF base≈2.16b ; Y1≈1.78b ; Y5≈1.27b
[DCF] Fair Price = 7.00 (EV 18.52b - Net Debt 12.17b = Equity 6.35b / Shares 907.6m; r=9.40% [WACC]; 5y FCF grow -21.37% → 2.90% )
EPS Correlation: -79.97 | EPS CAGR: -15.13% | SUE: -0.57 | # QB: 0
Revenue Correlation: -50.65 | Revenue CAGR: -2.72% | SUE: -0.08 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.57 | Chg7d=+0.001 | Chg30d=+0.072 | Revisions Net=+14 | Analysts=26
EPS current Year (2026-12-31): EPS=6.42 | Chg7d=+0.006 | Chg30d=+0.256 | Revisions Net=+22 | Growth EPS=+17.8% | Growth Revenue=+10.8%
EPS next Year (2027-12-31): EPS=7.68 | Chg7d=+0.009 | Chg30d=+0.165 | Revisions Net=+15 | Growth EPS=+19.7% | Growth Revenue=+10.3%
[Analyst] Revisions Ratio: +0.70 (17 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.5% (Discount Rate 10.1% - Earnings Yield 2.6%)
[Growth] Growth Spread = +1.5% (Analyst 9.0% - Implied 7.5%)
P/E Forward = 33.67
P/S = 10.8997
P/B = 11.8584
P/EG = 1.7117
Revenue TTM = 17.68b USD
EBIT TTM = 6.25b USD
EBITDA TTM = 8.25b USD
Long Term Debt = 13.55b USD (from longTermDebt, last quarter)
Short Term Debt = 619.0m USD (from shortTermDebt, last quarter)
Debt = 15.39b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.17b USD (from netDebt column, last quarter)
Enterprise Value = 203.24b USD (192.73b + Debt 15.39b - CCE 4.88b)
Interest Coverage Ratio = 11.52 (Ebit TTM 6.25b / Interest Expense TTM 543.0m)
EV/FCF = 78.08x (Enterprise Value 203.24b / FCF TTM 2.60b)
FCF Yield = 1.28% (FCF TTM 2.60b / Enterprise Value 203.24b)
FCF Margin = 14.72% (FCF TTM 2.60b / Revenue TTM 17.68b)
Net Margin = 28.28% (Net Income TTM 5.00b / Revenue TTM 17.68b)
Gross Margin = 57.02% ((Revenue TTM 17.68b - Cost of Revenue TTM 7.60b) / Revenue TTM)
Gross Margin QoQ = 55.89% (prev 57.42%)
Tobins Q-Ratio = 5.88 (Enterprise Value 203.24b / Total Assets 34.59b)
Interest Expense / Debt = 0.92% (Interest Expense 141.0m / Debt 15.39b)
Taxrate = 15.23% (209.0m / 1.37b)
NOPAT = 5.30b (EBIT 6.25b * (1 - 15.23%))
Current Ratio = 4.35 (Total Current Assets 13.75b / Total Current Liabilities 3.16b)
Debt / Equity = 0.95 (Debt 15.39b / totalStockholderEquity, last quarter 16.27b)
Debt / EBITDA = 1.47 (Net Debt 12.17b / EBITDA 8.25b)
Debt / FCF = 4.67 (Net Debt 12.17b / FCF TTM 2.60b)
Total Stockholder Equity = 16.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.27% (Net Income 5.00b / Total Assets 34.59b)
RoE = 30.44% (Net Income TTM 5.00b / Total Stockholder Equity 16.43b)
RoCE = 20.86% (EBIT 6.25b / Capital Employed (Equity 16.43b + L.T.Debt 13.55b))
RoIC = 17.57% (NOPAT 5.30b / Invested Capital 30.17b)
WACC = 9.40% (E(192.73b)/V(208.12b) * Re(10.09%) + D(15.39b)/V(208.12b) * Rd(0.92%) * (1-Tc(0.15)))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.11%
[DCF] Terminal Value 69.40% ; FCFF base≈2.16b ; Y1≈1.78b ; Y5≈1.27b
[DCF] Fair Price = 7.00 (EV 18.52b - Net Debt 12.17b = Equity 6.35b / Shares 907.6m; r=9.40% [WACC]; 5y FCF grow -21.37% → 2.90% )
EPS Correlation: -79.97 | EPS CAGR: -15.13% | SUE: -0.57 | # QB: 0
Revenue Correlation: -50.65 | Revenue CAGR: -2.72% | SUE: -0.08 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.57 | Chg7d=+0.001 | Chg30d=+0.072 | Revisions Net=+14 | Analysts=26
EPS current Year (2026-12-31): EPS=6.42 | Chg7d=+0.006 | Chg30d=+0.256 | Revisions Net=+22 | Growth EPS=+17.8% | Growth Revenue=+10.8%
EPS next Year (2027-12-31): EPS=7.68 | Chg7d=+0.009 | Chg30d=+0.165 | Revisions Net=+15 | Growth EPS=+19.7% | Growth Revenue=+10.3%
[Analyst] Revisions Ratio: +0.70 (17 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.5% (Discount Rate 10.1% - Earnings Yield 2.6%)
[Growth] Growth Spread = +1.5% (Analyst 9.0% - Implied 7.5%)